MILLTRUST INTERNATIONAL
 

There is No Universal Diet

May 14, 2020

BY Alexander Kalis
MANAGING PARTNER

Viome, an investee company through Milltrust’s partnership with Cerracap Ventures, is focused on disrupting healthcare by “making illness optional”. The Viome test is a breakthrough microbiome bacteria, epigenetics, epigenome and epigenomics technology.

Milltrust has a block of USD 5 million at a 20 percent discount to the last raise. Contact us for more information.

Categories: News

Tags: